Concord Medical Services Holdings Limited logo

Concord Medical Services Holdings Limited

CCM

NYSEHealthcareMedical - Care Facilities

Previous close

$5.44

+$0.19 · +3.62%

Aug 21, 3:59 PM ET

CCM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

54

Fair Value

Momentum

53

Neutral

Sentiment

52

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People’s Republic of China. It operates in two segments, Network and Hospital. The company’s services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
CN
CEO
Jianyu Yang
Listed since
Dec 11, 2009
Employees
610

Market position

Day range

Current $5.44

52-week range

Current $5.44

Open
$5.1083
Previous close
$5.25
Volume
27.72K
0.45× average
Average volume
61.44K
Average daily volume
Market cap
792.14K USD
Beta
-0.95
Market reference 1
50-day average
$4.634
+17.39% above average
200-day average
$4.3273
+25.71% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.34B CNY
P/E (TTM)
-0.04×
P/B (TTM)
-0×
P/S (TTM)
0.01×
EV / EBITDA
-46.55×
Earnings yield
-2361.38%
Free cash flow yield
-7458.79%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
6.88%
Operating margin
-40.87%
Net margin
-21.25%
Return on equity
4.41%
Return on assets
-1.42%
Return on invested capital
-4.26%

Financial health

Debt / equity
-1.73×
Current ratio
0.48×

Earnings

Latest EPS result
-12.81

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0.54-16.7-32.85-49Q2 '23Q3 '23Q3 '23Q1 '24Q2 '24Q4 '24Q4 '24Q2 '25
Q2 2023, reported May 5, 2023: actual -45.42, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Sep 4, 2023: actual -43.11, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Sep 22, 2023: actual -0.972, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 26, 2024: actual -1, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Apr 19, 2024: actual -0.818, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Oct 28, 2024: actual -0.665, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Dec 25, 2024: actual -0.639, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Apr 25, 2025: actual -12.81, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates36.24M27.36M18.49M9.61MQ2 '23No estimateQ3 '23MissQ3 '23MissQ1 '24No estimateQ2 '24No estimateQ4 '24MissQ4 '24No estimateQ2 '25No estimate
Q2 2023, reported May 5, 2023: actual 20.69M USD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Sep 4, 2023: actual 19.63M USD, estimate 34.39M USD, surprise -42.91%, Miss. Q3 2023, reported Sep 22, 2023: actual 17.31M USD, estimate 34.39M USD, surprise -49.67%, Miss. Q1 2024, reported Mar 26, 2024: actual 17.85M USD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Apr 19, 2024: actual 15.13M USD, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Oct 28, 2024: actual 11.77M USD, estimate 34.39M USD, surprise -65.78%, Miss. Q4 2024, reported Dec 25, 2024: actual 11.31M USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Apr 25, 2025: actual 13.78M USD, estimate —, surprise —, Comparison unavailable.

CCM peers

Continue in GoAI

Research CCM

research.disclaimer